Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial

Journal:
The Lancet
Published:
DOI:
10.1016/s0140-6736(25)01044-x
Affiliations:
6
Authors:
9
Go to article
Institutions Authors Share
Lilly, United States of America (USA)
4.000000
 0.44
Jinnouchi Hospital, Japan
1.000000
 0.11
AMCR Institute, United States of America (USA)
1.000000
 0.11
Scripps Health, United States of America (USA)
1.000000
 0.11
Park Nicollet International Diabetes Center, United States of America (USA)
1.000000
 0.11
Arkansas Diabetes and Endocrinology Center, United States of America (USA)
1.000000
 0.11
Interested in Clinical Sciences?